Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 240 participants.

Also called NCT07298993

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07298993
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07298993. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-02 (actual); primary completion 2029-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Acronym
DEPRESCRIBE
Condition
Heart Failure
Condition
HFpEF
Intervention (Drug)
Placebo (matching)
Intervention (Drug)
Beta-blockers
Lead sponsor
Weill Medical College of Cornell University (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)
Collaborator
Kaiser Foundation Research Institute (class: other)

Record details

Record id
cardio:ct-nct07298993
Content hash
d8106feb8e8a4e88c661481e7c72524fcb4b774c55492e0c5de4f467fe789d09